Ana Oaknin

42PUBLICATIONS
288CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Social epidemiologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Apr 09, 2026
Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker, Jung-Yun Lee, Do-Youn Oh

|Apr 08, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno

|Sep 19, 2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.

Munetaka Takekuma, Shin Nishio, Satoshi Yamaguchi

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Apr 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

Joyce F Liu, Nicoletta Colombo, Amit M Oza

Pageof 7

Frequent Collaborators

8 joint publications

Susana N Banerjee

8 joint publications

Toon Van Gorp

7 joint publications

Domenica Lorusso

7 joint publications

Nicoletta Colombo